MERSEYSIDE-based drug development company Redx Pharma is celebrating a breakthrough in its research into the treatments of cancers, including pancreative, breast and head and neck cancer.
It has announced it has reached pre-clinical proof of the concept stage with an advanced oncology lead, with has the potential to tackle the hard-to-treat cancers.
Dr Neil Murray, CEO of Redx, said: “We’re very pleased to have reached pre-clinical proof of concept with this very promising programme. The cancers it has the potential to tackle are some of the most hard-to-treat.
See the article in full at BusinessDesk.com